Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III
Value in Health, 06/26/09
Stevenson M et al. - Bosentan is likely to be a more cost-effective first-line therapy for patients with PAH FC III in the UK than no active intervention.
Today in Economics of Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Medicare cracks down on false claims
Medical Economics, 11/02/09
2009 earnings survey: How do you compare
Medical Economics, 09/29/09
Higher hospital spending linked to better outcomes
American Medical News , 11/06/09